TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34116270

Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced ovarian failure (CIOF) after anthracycline/taxane-based chemotherapy
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Regain of premenopausal hormone levels after chemotherapy
Number of subjects: 696

Group type: COMPARATOR
Intervention: Disease-free survival (DFS) without CIOF
Number of subjects: 696

Group type: COMPARATOR
Intervention: Disease-free survival (DFS) in hormone receptor positive patients
Number of subjects: 696

Group type: COMPARATOR
Intervention: Disease-free survival (DFS) in patients aged <30 years
Number of subjects: 696
Study: 32147076

Group type: EXPERIMENTAL
Intervention: Green coffee extract (GCE) 400 mg daily for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 35301381

Group type: EXPERIMENTAL
Intervention: Propofol-based total intravenous anesthesia (TIVA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Desflurane inhalation anesthesia
Number of subjects: 120
Study: 32990215

Group type: EXPERIMENTAL
Intervention: Active treatment (370 subjects)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo (126 subjects)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 496

Group type: COMPARATOR
Intervention: Active treatment and Placebo
Number of subjects: 496
Study: 35334388

Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vasopressin administration
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 34959949

Group type: EXPERIMENTAL
Intervention: Carrot-derived rhamnogalacturonan-I (cRG-I) at 0.3 g/day
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Carrot-derived rhamnogalacturonan-I (cRG-I) at 1.5 g/day
Number of subjects: 177

Group type: COMPARATOR
Intervention: Carrot-derived rhamnogalacturonan-I (cRG-I) at 0 g/day (control)
Number of subjects: 177
Study: 36453726

Group type: EXPERIMENTAL
Intervention: Bone channeling augmentation
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard repair
Number of subjects: 168
Study: 33655813

Group type: EXPERIMENTAL
Intervention: Virtual reality gaming and physiotherapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 38
Study: 33642441

Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg/day)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 223
Study: 34602065

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention for 10 weeks (0-10 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (delayed exercise) for 10 weeks (10-20 weeks)
Number of subjects: 40
Study: 32889494

Group type: EXPERIMENTAL
Intervention: High closeness induction
Number of subjects: 69

Group type: COMPARATOR
Intervention: Low closeness induction
Number of subjects: 69
Study: 33067779

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 6110

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 6110

Group type: EXPERIMENTAL
Intervention: Multiple statin treatment
Number of subjects: 6110

Group type: EXPERIMENTAL
Intervention: Combined lipophilic and hydrophilic statin
Number of subjects: 6110

Group type: EXPERIMENTAL
Intervention: Cumulative defined daily dose (cDDD) > 430
Number of subjects: 6110
Study: 33340779

Group type: EXPERIMENTAL
Intervention: 2D‐SWE examination with reliable measurements
Number of subjects: 788
Study: 32127275

Group type: EXPERIMENTAL
Intervention: High heparin dose (600 IU/kg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Low heparin dose (300 IU/kg)
Number of subjects: 63
Study: 34003132

Group type: EXPERIMENTAL
Intervention: Fourth-generation synchronous telehealth program
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control group (no telehealth program)
Number of subjects: 391
Study: 32683997

Group type: EXPERIMENTAL
Intervention: CALM intervention
Number of subjects: 74
Study: 36050617

Group type: EXPERIMENTAL
Intervention: Laparoscopic paragastric autonomic neural blockade (PG-ANB)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (no PG-ANB)
Number of subjects: 145
Study: 34018181

Group type: EXPERIMENTAL
Intervention: Implementation of a quality improvement (QI) program including distance-learning strategies, involvement of a champion, regular submission of data on hospitalizations and root cause analyses of transfers, and training, feedback and support.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Implementation of a quality improvement (QI) program
Number of subjects: 71

Group type: COMPARATOR
Intervention: Low-performing NHs (control group)
Number of subjects: 71
Study: 34511049

Group type: EXPERIMENTAL
Intervention: Probiotic (Lab4) plus 50 mg vitamin C
Number of subjects: 171
Study: 34213106

Group type: EXPERIMENTAL
Intervention: Gas chromatography-tandem mass spectrometry (GC-MS/MS) method for cholesterol and tocopherols detection
Number of subjects: 20

Group type: COMPARATOR
Intervention: National standard methods (GB 5009.82-2016, GB 5009.128-2016)
Number of subjects: 20
Study: 34497506

Group type: EXPERIMENTAL
Intervention: BEAR‐H1 lower‐limb exoskeletal robot
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine training for walking (Control)
Number of subjects: 130
Study: 33213530

Group type: EXPERIMENTAL
Intervention: Favipiravir plus standard treatment for COVID‐19 (loading dose of 3600mg on day 1, followed by 800mg 12 hours apart for 9 days)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Standard treatment for COVID‐19 (at the discretion of the treating clinician)
Number of subjects: 302
Study: 36180450

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 144
Study: 34151607

Group type: EXPERIMENTAL
Intervention: Inpatient isolation treatment for COVID-19 patients
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Psychological experiences of COVID-19 patients
Number of subjects: 10
Study: 36059240

Group type: EXPERIMENTAL
Intervention: Negative narrative condition
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Neutral narrative condition
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Positive narrative condition
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 1030
Study: 34130022

Group type: EXPERIMENTAL
Intervention: Dextrose
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High Carbohydrate (HC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High Protein (HP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High Fat (HF)
Number of subjects: 120
Study: 36467732

Group type: EXPERIMENTAL
Intervention: Pregnant women in third trimester (P3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pregnant women in second trimester (P2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pregnant women in second trimester (P2) and third trimester (P3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-pregnant women (N)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pregnant women in first trimester (P1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study: 35767081

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32786068

Group type: EXPERIMENTAL
Intervention: Running at 95% VO2max
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cycling at 95% VO2max
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Running at 50% VO2max
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cycling at 65% VO2max
Number of subjects: 26
Study: 34416183

Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) control
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) fluctuation
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: IOP fluctuation in primary angle closure glaucoma
Number of subjects: 280
Study: 32900856

Group type: EXPERIMENTAL
Intervention: NP-administered POCUS
Number of subjects: 204
Study: 35906645

Group type: EXPERIMENTAL
Intervention: Enhanced usual care plus GAIN intervention (8-week interdisciplinary program)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Enhanced usual care only
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Self-reported outcomes
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Registry-based outcomes
Number of subjects: 180
Study: 32660658

Group type: EXPERIMENTAL
Intervention: High-dose DHA (60 mg/kg per d)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Soya oil (control)
Number of subjects: 120
Study: 36084065

Group type: COMPARATOR
Intervention: Conventional IVES
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: IVES with an open circuit
Number of subjects: 76
Study: 32505593

Group type: EXPERIMENTAL
Intervention: High-pitch non-ECG-triggered chest CT
Number of subjects: 1000
Study: 34706340

Group type: EXPERIMENTAL
Intervention: Heavy resisted sprint training (RST)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unresisted sprint training (UST)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (ordinary soccer training and match play)
Number of subjects: 24
Study: 34836084

Group type: EXPERIMENTAL
Intervention: SoMe social media literacy program
Number of subjects: 892

Group type: COMPARATOR
Intervention: Control sessions (lessons as usual)
Number of subjects: 892
Study: 35038343

Group type: EXPERIMENTAL
Intervention: Face-to-face periodic occupational health screening
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Electronic screening with targeted follow-up
Number of subjects: 1077
Study: 33287816

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) intravenously guttae for 7 days plus standard treatment: 1.5 mg/kg/day [day 1–3], 1 mg/kg/day [day 4–5], and 0.5 mg/kg/day [day 6–7]
Number of subjects: 171

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) treatment
Number of subjects: 171
Study: 35466486

Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 241
Study: 34719279

Group type: EXPERIMENTAL
Intervention: Standard dressings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy
Number of subjects: 0
Study: 35795177

Group type: EXPERIMENTAL
Intervention: Small-sided games (SSG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-intensity interval training (HIIT)
Number of subjects: 40
Study: 34480412

Group type: EXPERIMENTAL
Intervention: Physical activity advice or exergame intervention
Number of subjects: 480

Group type: COMPARATOR
Intervention: Not randomized to exergaming
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Baseline 6MWT <300m
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: New York Heart Association class III/IV
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Higher levels of serum creatinine
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Lower cognitive function
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Fewer anxiety symptoms
Number of subjects: 480
Study: 32725411

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated drug-eluting stents (DES)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty with bail-out bare-metal stents (PTA ± BMS)
Number of subjects: 137
Study: 35022480

Group type: EXPERIMENTAL
Intervention: Lymphatic Contrast Enhanced Ultrasound (LCEUS) with Sonazoid injection
Number of subjects: 20
Study: 33601934

Group type: EXPERIMENTAL
Intervention: SNAPSHOT intervention (32.5 contact hours)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Newsletter-only control group
Number of subjects: 132
Study: 32267450

Group type: EXPERIMENTAL
Intervention: Consumption of sugar-sweetened beverages
Number of subjects: 2172

Group type: COMPARATOR
Intervention: Non-consumption of sugar-sweetened beverages
Number of subjects: 2172
Study: 35585813

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 33407177

Group type: EXPERIMENTAL
Intervention: CnLN metastasis
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: pN2 patients with CnLN metastasis
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: pN3 patients with CnLN metastasis
Number of subjects: 1178
Study: 36362489

Group type: EXPERIMENTAL
Intervention: Doll Therapy Intervention (DTI)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Sham Intervention (SI)
Number of subjects: 134
Study: 33217829

Group type: EXPERIMENTAL
Intervention: Propofol with midazolam (MP)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Sevoflurane with midazolam (MS)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Propofol without midazolam (P)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Sevoflurane without midazolam (S)
Number of subjects: 226
Study: 35389942

Group type: EXPERIMENTAL
Intervention: Floatation-REST
Number of subjects: 11

Group type: COMPARATOR
Intervention: Passive sensory-stimulating control
Number of subjects: 11
Study: 34301655

Group type: EXPERIMENTAL
Intervention: Tailored educational intervention for general practitioners (GPs) including general training of PIMs and distribution of PIMs handbook
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine practice by GPs in control arm
Number of subjects: 20
Study: 35045835

Group type: EXPERIMENTAL
Intervention: Enhanced autonomy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Routine autonomy
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: External focus of attention
Number of subjects: 133

Group type: COMPARATOR
Intervention: Internal focus of attention
Number of subjects: 133
Study: 34639351

Group type: EXPERIMENTAL
Intervention: MI Varnish (5% sodium fluoride with CPP‐ACP)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Clinpro White Varnish (5% sodium fluoride with fTCP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 58
Study: 34543161

Group type: EXPERIMENTAL
Intervention: Valsartan 4 mg/kg/day
Number of subjects: 127

Group type: COMPARATOR
Intervention: Valsartan 0.25 mg/kg/day
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Valsartan 4 mg/kg/day (CKD subgroup)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Valsartan 0.25 mg/kg/day (CKD subgroup)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Valsartan 4 mg/kg/day (non-CKD subgroup)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Valsartan 0.25 mg/kg/day (non-CKD subgroup)
Number of subjects: 127
Study: 33262414

Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl 100 µg
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 33467972

Group type: EXPERIMENTAL
Intervention: Individual reminiscence therapy (RT), 26 sessions, twice a week for 13 weeks
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group maintained treatment as usual
Number of subjects: 148
Study: 34445009

Group type: EXPERIMENTAL
Intervention: Portfolio Diet Score (PDS) assessed by food frequency questionnaire (FFQ)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Portfolio Diet Score (PDS) from FFQ
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Portfolio Diet Score (PDS) from FFQ and 7DDR
Number of subjects: 652
Study: 35248683

Group type: EXPERIMENTAL
Intervention: Best Practices plus Financial Incentives (BP + FI)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Best Practices (BP)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Never-Smokers (NS)
Number of subjects: 249
Study: 36463502

Group type: EXPERIMENTAL
Intervention: Retraining programme (knowledge and practical assessment and one-on-one retraining session)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 130
Study: 33337947

Group type: EXPERIMENTAL
Intervention: α-hydroxyisocaproic acid
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: β-hydroxy-β-methylbutyrate free acid
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: calcium β-hydroxy-β-methylbutyrate
Number of subjects: 53

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 53
Study: 32087686

Group type: EXPERIMENTAL
Intervention: Paravertebral catheter analgesia
Number of subjects: 192

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia
Number of subjects: 192
Study: 33742730

Group type: EXPERIMENTAL
Intervention: Two dosages of hemofiltration for continuous RRT
Number of subjects: 211
Study: 32788558

Group type: EXPERIMENTAL
Intervention: Oliceridine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 30
Study: 33306565

Group type: EXPERIMENTAL
Intervention: lamivudine-tenofovir
Number of subjects: 224

Group type: COMPARATOR
Intervention: lamivudine alone
Number of subjects: 224
Study: 33273055

Group type: EXPERIMENTAL
Intervention: T21 policy implementation
Number of subjects: 0
Study: 33657099

Group type: EXPERIMENTAL
Intervention: Adjunctive dexamethasone
Number of subjects: 451
Study: 32452181

Group type: EXPERIMENTAL
Intervention: Conservative treatment (Fengshi spine fixed-point rotation reduction plus routine dehydration and anti-inflammation)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: VAS score
Number of subjects: 59
Study: 35015264

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) for 1 hour every 8 hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional phototherapy (Control)
Number of subjects: 50
Study: 33527419

Group type: EXPERIMENTAL
Intervention: Perceived Movement Skill Competence (PMSC) and Stability (PMSC_Stability) pictorial scales
Number of subjects: 904

Group type: COMPARATOR
Intervention: Körperkoordinations test für Kinder (KTK)
Number of subjects: 904
Study: 32320088

Group type: EXPERIMENTAL
Intervention: Risankizumab (150 mg)
Number of subjects: 797

Group type: COMPARATOR
Intervention: Ustekinumab (weight-based; 45 or 90 mg)
Number of subjects: 797
Study: 35418312

Group type: EXPERIMENTAL
Intervention: Margetuximab plus chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Margetuximab plus chemotherapy in CD16A-158F allele carriers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 0
Study: 32870298

Group type: EXPERIMENTAL
Intervention: Low tidal volume group (6 mL/kg predicted body weight)
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Conventional tidal volume group (10 mL/kg predicted body weight)
Number of subjects: 1236
Study: 34229578

Group type: EXPERIMENTAL
Intervention: Person-centered care (PCC)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 47
Study: 34380867

Group type: COMPARATOR
Intervention: Single-dose regimen of 4 L PEG (Nulytely) administered a day before the procedure
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Split-dose regimen of 2 L PEG (Nulytely) given a day before and 2 L on the day of the procedure
Number of subjects: 240

Group type: COMPARATOR
Intervention: Single-dose regimen of 4 L PEG (Nulytely)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Split-dose regimen of 2 L PEG (Nulytely)
Number of subjects: 240
Study: 32008429

Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 162
Study: 34371175

Group type: EXPERIMENTAL
Intervention: Immune-enhancing diet
Number of subjects: 116

Group type: COMPARATOR
Intervention: Blenderized diet
Number of subjects: 116
Study: 36054520

Group type: EXPERIMENTAL
Intervention: Energy drink-specific warning label (risk of cardiac effects)
Number of subjects: 435

Group type: COMPARATOR
Intervention: General sugary drink warning label (risk of obesity)
Number of subjects: 435
Study: 33957682

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study: 32932235

Group type: EXPERIMENTAL
Intervention: Flavonoid supplementation (678 mg FLAVs including quercetin, green tea catechins, and bilberry anthocyanins)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Flavonoid supplementation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 33789955

Group type: EXPERIMENTAL
Intervention: Severe dysmenorrhoea group
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Overall pain
Number of subjects: 188
Study: 34107492

Group type: EXPERIMENTAL
Intervention: GIC sealants
Number of subjects: 77

Group type: COMPARATOR
Intervention: Unsealed MIH‐affected molars
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: MIH‐affected molars with yellow-brown opacities
Number of subjects: 77
Study: 32113735

Group type: EXPERIMENTAL
Intervention: ICU diary
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Discharge summary
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ICU diary and discharge summary
Number of subjects: 61
Study: 35622137

Group type: EXPERIMENTAL
Intervention: Individually tailored nutritional guidance for FCs
Number of subjects: 63
Study: 34497851

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Gait Training (RT group, n=27)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional Overground Gait Training (PT group, n=27)
Number of subjects: 54
Study: 35759537

Group type: COMPARATOR
Intervention: Standardized home‐based gut‐directed hypnosis exercises with compact disc (CD)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Individual hypnotherapy (iHT) by a therapist
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Both groups (CD and iHT)
Number of subjects: 227
Study: 33340297

Group type: EXPERIMENTAL
Intervention: Fampridine (10 mg, 2 times a day for 24 weeks)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo (same administration as fampridine)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Fampridine (10 mg, 2 times a day for 12 weeks after placebo)
Number of subjects: 126
Study: 34565292

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EX) for 60 minutes at 75% of age-predicted maximum heart rate
Number of subjects: 22

Group type: COMPARATOR
Intervention: No exercise (NE)
Number of subjects: 22
Study: 34888401

Group type: EXPERIMENTAL
Intervention: Favipiravir (1800mg per os twice a day on day 1, followed by 1000mg b.i.d. for 13 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 50